Dr Daniel Chan


MBBS (Honours) 2000 –National University of Singapore School of Medicine
MRCP (UK) 2004 –Royal College of Physicians United Kingdom
FAMS (Medical Oncology) 2009 –Academy of Medicine Singapore
FRCP (Edinburgh) 2015 – Royal College of Physicians Edinburgh

 

“My practice is personalised and innovative. I view every patient almost like a friend or relative where we give the utmost care.”

Dr Chan graduated with the rare distinction of honours from National University of Singapore (NUS) School of Medicine. He was further trained in internal medicine and obtained the MRCP (UK) in 2004. He received his medical oncology specialist training with the National University Cancer Institute of Singapore. He finished his final year of fellowship in the USA at the prestigious University of California, Los Angeles (UCLA) and Cedars- Sinai Medical Centre. He honed his medical oncology clinical expertise at UCLA and Cedars-Sinai with Dr Ronald Natale (lung cancer), Dr Michael Lill (lymphoma), Dr Charles Forscher (sarcoma) and Dr Albert Lai (neuro-oncology) under an endowment grant from the National University Hospital of Singapore. He also pursued research in the laboratory of world-famous haematologist-oncologist Professor Phillip Koeffler under a National Medical Research Council Overseas Fellowship.

Upon his return, he was a consultant in medical oncology at the National University Cancer Institute Singapore and director of undergraduate education (medical oncology) at the National University of Singapore. He was also actively involved in cancer research at the Cancer Science Institute Singapore. He is a member of the American Society of Clinical Oncology, and in 2015 he was elected to be a fellow in the Royal College of Physicians Edinburgh.

Achievements and Accolades

  • Published in international peer reviewed journals including Proceedings of the National Academy of Sciences (USA), Annals of Oncology and Investigational New Drugs on breast cancer, melanoma, thyroid cancer, nasopharyngeal cancer and myeloproliferative neoplasms.
  • Written a book chapter on breast cancer in “Oncogene and Cancer – From Bench to Clinic“
  • Was involved as a co-investigator in numerous trials of new oncology drugs and held a national research grant in triple-negative breast cancer in NCIS.
  • Awarded the Excellent Service Award (EXSA) and STAR award (from SPRING Singapore) on multiple occasions for exemplary service to his patients.
  • First in South Asia to use the PD-1 immunotherapy drug (Pembrolizumab) in clinical practice

Sub specialty interests: Breast, lung and colon cancers, lymphoma, neuro-oncology and sarcoma